NEOS Investment Management LLC Boosts Holdings in Moderna, Inc. $MRNA

NEOS Investment Management LLC increased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 52.2% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 38,662 shares of the company’s stock after purchasing an additional 13,258 shares during the period. NEOS Investment Management LLC’s holdings in Moderna were worth $999,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in MRNA. GSA Capital Partners LLP lifted its stake in Moderna by 216.3% in the third quarter. GSA Capital Partners LLP now owns 38,922 shares of the company’s stock worth $1,005,000 after purchasing an additional 26,617 shares during the last quarter. Fifth Third Bancorp increased its holdings in shares of Moderna by 52.9% in the third quarter. Fifth Third Bancorp now owns 32,088 shares of the company’s stock worth $829,000 after buying an additional 11,108 shares during the period. State of New Jersey Common Pension Fund D increased its holdings in shares of Moderna by 4.0% in the third quarter. State of New Jersey Common Pension Fund D now owns 124,082 shares of the company’s stock worth $3,205,000 after buying an additional 4,744 shares during the period. Public Sector Pension Investment Board lifted its stake in shares of Moderna by 7.1% in the 3rd quarter. Public Sector Pension Investment Board now owns 74,677 shares of the company’s stock valued at $1,929,000 after acquiring an additional 4,939 shares during the last quarter. Finally, Cibc World Market Inc. boosted its holdings in Moderna by 2.8% during the 3rd quarter. Cibc World Market Inc. now owns 25,832 shares of the company’s stock valued at $667,000 after acquiring an additional 700 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA will review Moderna’s mRNA flu vaccine application after an initial refusal-to-file, with regulators now targeting a decision by Aug. 5, 2026 — a reversal that boosts the commercial outlook for a new recurring vaccine market and spurred an earlier jump in the stock. Moderna Stock Jumps After FDA Reverses Course on Flu Shot
• Positive Sentiment: Goldman Sachs analyst flagged upside for MRNA, an institutional vote of confidence that can support sentiment and buying interest. Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
• Neutral Sentiment: Moderna will present at TD Cowen and Barclays healthcare conferences in March — routine investor access that may provide more management detail but is unlikely by itself to move the stock dramatically. Moderna to Present at Upcoming Conferences in March 2026
• Negative Sentiment: BioNTech sued Moderna in Delaware federal court alleging Moderna’s mNexspike infringes a patent tied to BioNTech/Pfizer’s Comirnaty—new litigation increases legal risk, potential damages or injunctions, and heightens competitive/legal uncertainty for Moderna’s COVID-19/respiratory vaccine portfolio. BioNTech sues Moderna for patent infringement over COVID-19 shots
• Negative Sentiment: A court recently rejected two of Moderna’s defenses in its patent dispute with Arbutus, representing another legal setback that could increase exposure and costs from long-running mRNA technology litigation. Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Moderna Stock Performance

NASDAQ:MRNA opened at $49.87 on Friday. The company has a quick ratio of 3.22, a current ratio of 3.29 and a debt-to-equity ratio of 0.07. The firm’s fifty day simple moving average is $39.02 and its 200 day simple moving average is $30.44. The stock has a market cap of $19.49 billion, a P/E ratio of -6.86 and a beta of 1.32. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $55.20.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, February 13th. The company reported ($2.11) EPS for the quarter, topping the consensus estimate of ($2.79) by $0.68. The business had revenue of $678.00 million during the quarter, compared to analyst estimates of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The company’s revenue for the quarter was down 33.2% on a year-over-year basis. During the same period in the prior year, the business earned ($2.91) EPS. As a group, research analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MRNA. Wolfe Research reaffirmed an “underperform” rating and issued a $17.00 price target on shares of Moderna in a research note on Thursday, November 20th. Leerink Partners restated an “underperform” rating on shares of Moderna in a report on Friday, January 30th. Evercore set a $35.00 target price on shares of Moderna in a research note on Tuesday. Morgan Stanley set a $30.00 price target on shares of Moderna in a report on Monday. Finally, Piper Sandler reissued an “overweight” rating on shares of Moderna in a report on Monday, December 1st. Two equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have given a Sell rating to the company. According to MarketBeat.com, Moderna currently has an average rating of “Reduce” and a consensus price target of $31.47.

Insider Buying and Selling at Moderna

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total transaction of $703,186.44. Following the transaction, the director owned 3,924 shares in the company, valued at approximately $115,679.52. This represents a 85.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.90% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.